Lack of pharmacologic interaction between paroxetine and alprazolam at steady state in healthy volunteers

Journal of Clinical Psychopharmacology

Volumn 24, Issue 3, 2004, Pages 268-276

  Calvo, Gonzalo ^a,d   García Gea, Consuelo ^b   Luque, Antonio ^c   Morte, Adelaida ^b   Dal Ré, Rafael ^c   Barbanoj, Manel ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Research Institute   (Spain)

^c GLAXOSMITHKLINE   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; PAROXETINE;

ADULT; APPETITE DISORDER; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIPLOPIA; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN EXPERIMENT; INCIDENCE; MALE; MOOD; MULTIPLE DRUG DOSE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; VISUAL ANALOG SCALE;

ADULT; ALPRAZOLAM; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CHI-SQUARE DISTRIBUTION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; PAROXETINE; PSYCHOMOTOR PERFORMANCE;

EID: 2442711592     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000125689.05091.c6     Document Type: Article

References (35)

1. Argyropoulos SV, Nutt DJ. The use of benzodiazepines in anxiety and other disorders. Eur Neuropsychopharmacol. 1999;9(suppl 6):S407-S412.
2. Fraser AD. Use and abuse of the benzodiazepines. Ther Drug Monit. 1998;20:481-489.
3. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med. 1993;328:1398-1405.
4. Gorman JM. The use of newer antidepressants for panic disorder. J Clin Psychiatry. 1997;58(suppl 14):54-58.
5. Westenberg HG. Developments in the drug treatment of panic disorder: what is the place of the selective serotonin reuptake inhibitors? J Affect Disord. 1996;40:85-93.
6. Wagstaff AJ, Cheer SM, Matheson AJ, et al. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs. 2002;62:655-703.
7. Layton ME, Dager SR. Optimum treatment of panic disorder. CNS Drugs. 1994;2:208-215.
8. Gregor KJ, Way K, Young CH, et al. Concomitant use of selective serotonin reuptake inhibitors with other cytochrome P450 2D6 or 3A4 metabolized medications: how often does it really happen? J Affect Disord. 1997;46:59-67.
9. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J Clin Psychopharmacol. 1999;19(suppl 1):23S-35S.
10. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet. 1999;32 (suppl 1):1-21.
11. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270: 414-423.
12. Senn S. Cross-over Trials in Clinical Research. Chichester: Wiley; 1993:244-248.
13. Shah VP, Midha KK, Dighe S, et al, Conference report. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. J Pharm Sci. 1992;81:309-312.
14. Allen GD. PC modfit for Windows. A Pharmacokinetic Computer Program ARTPAC; 1995-1996.
15. Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990;28:72-80.
16. Gorski JC, Jones DR, Hamman MA, et al. Biotransformation of alprazolam by members of the human cytochrome P450 3A subfamily. Xenobiotica. 1999;29:931-944.
17. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, et al. Alprazolam is another substrate for human cytochrome P450-3A isoforms. J Clin Psychopharmacol. 1998;18:256.
18. Yasui N, Otani K, Kaneko S, et al. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther. 1996;59:514-519.
19. von Moltke LL, Greenblatt DJ, Court MH, et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with the selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol. 1995;15:125-131.
20. von Moltke LL, Greenblatt DJ, Duan SX, et al. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol. 1996;16:104-112.
21. Rasmussen BB, Mäenpää J, Pelkonen O, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol. 1995;39:151-159.
22. Martin DE, Zussman BD, Everitt DE, et al. Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. J Clin Pharmacol. 1997;17:451-459.
23. Andersen BB, Mikkelsen M, Vesterager A, et al. No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy Res. 1991;10:201-204.
24. Sproule BA, Naranjo CA, Brenmer KE, et al. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet. 1997;33:454-471.
25. Greene DS, Salazar DE, Dockens RC, et al. Coadministration of nefazodone and benzodiazepines. III. A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol. 1995;15:399-408.
26. Lasher TA, Fleishaker JC, Steenwyk RC, et al. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology. 1991;104:323-327.
27. Greenblatt DJ, Preskorn SH, Cotreau MM, et al. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther. 1992;52:459-486.
28. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol. 1994;46:35-39.
29. Amchin J, Zarycranski W, Taylor KP, et al. Effect of venlafaxine on the pharmacokinetics of alprazolam. Psychopharmacol Bull. 1998;34: 211-219.
30. Preskorn SH, Greenblatt DJ, Harvey AT. Lack of effect of sertraline on the pharmacokinetics of alprazolam. J Clin Pharmacol. 2000;20: 585-586.
31. Hassan PC, Sproule BA, Naranjo CA, et al. Dose-response evaluation of the interaction between sertraline and alprazolam in vivo. J Clin Psychopharmacol. 2000;20:150-158.
32. Preskorn SH, Alderman J, Greenblatt DJ, et al. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. Psychopharmacol Bull. 1997;33:659-665.
33. Cooper SM, Jackson D, Loudon JM, et al. The psychomotor effects of paroxetine alone and in combination with haloperidol, amylobarbitone, oxazepam or alcohol. Acta Psychiatr Scand. 1989;80(suppl 350):53-55.
34. Bannister SJ, Houser VP, Hulse JD, et al. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand. 1989;80(suppl 350):102-106.
35. Kravitz HM, Fawcett J, Newman AJ. Alprazolam and depression: a review of risks and benefits. J Clin Psychiatry. 1993;54(suppl 1): 78-84.